Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I/II, Dual-Center, Open-Label Trial of the Safety and Efficacy of Tarceva™ (Erlotinib Hydrochloride) Plus Sirolimus in Patients With Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when
given together with sirolimus and to see how well they work in treating patients with
recurrent malignant glioma.
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
escalating doses of erlotinib hydrochloride in combination with sirolimus in adult
patients with malignant glioma, who are not receiving enzyme-inducing anti-epileptic
drugs (EIAED). (Phase I)
- Evaluate preliminary efficacy (response rate [RR], progression-free survival [PFS], and
overall survival [OS]) of erlotinib hydrochloride and sirolimus combination therapy in
glioblastoma multiforme (GMB)/gliosarcoma (GS) patients who are not undergoing surgery
at the time of recurrence or relapse (dose-expansion arm). (Phase II)
- Evaluate molecular determinants of response to the combination of erlotinib
hydrochloride and sirolimus, especially the roles of the mutation of EGFR (e.g., vIII
mutant, other somatic mutations of vIII, and mutation/deletion of PTEN).
Secondary
- To characterize the safety and tolerability of erlotinib hydrochloride and sirolimus
combination therapy in these patient populations.
- To characterize the single-dose and repeated-dose pharmacokinetic (PK) profiles of
erlotinib hydrochloride (in serum) and sirolimus (in whole blood) combination therapy in
these patient populations.
- To characterize, in pre- and/or post-treatment tumor samples, when available, expression
levels of total and activated phosphorylated proteins relevant to the EGFR, VEGFR, and
PI3K/mTOR signaling pathways, relevant downstream signaling network components, EGFR and
VEGFR-related ligands, apoptosis (TUNEL), cell cycle control, and proliferation.
- To assess pre- and/or post-treatment tumor samples, when available, for DNA-based
changes (e.g., EGFR [DNA] amplification, EGFR and EGFRvIII mutations, and
mutations/deletions in the PTEN gene) relevant to the molecular biology in GBM.
OUTLINE: Patients receive oral erlotinib hydrochloride and sirolimus once daily on days 1-28.
Treatment repeats every 28 days in the absence of disease progression or unacceptable
toxicity.
Patients undergo tumor tissue and blood sample collection periodically for pharmacological
and biological studies. Samples are analyzed for concentrations of erlotinib hydrochloride
and trough serum levels of sirolimus via HPLC, EGFR, EGFRvIII, PTEN and the phospho-specific
antibodies associated with the MAPK and PI3K pathways via IHC, and EGFRvIII and sequencing of
EGFR, PTEN and other critical genes via PCR, gene expression, and SNP analysis. Germline DNA
will also be used to distinguish polymorphisms from somatic mutations in gene sequenced.
After completion of study treatment, patients are followed periodically.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 |